Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-22-005446
Filing Date
2022-01-19
Accepted
2022-01-19 16:15:39
Documents
2
Period of Report
2022-01-17

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm223835-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm223835-1_3seq1.xml 3 1660
2 EXHIBIT 24 tm223835d1_ex24.htm EX-24 9052
  Complete submission text file 0001104659-22-005446.txt   12096
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Issuer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK REHOVOT L3 7670402
Business Address
Wiley Matthew T. (Reporting) CIK: 0001759703 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38410 | Film No.: 22538952